JACKSONVILLE, Fla., Aug. 25, 2005 (PRIMEZONE) -- Phlo Corporation (Pink Sheets:PHLC)("Phlo") announced today that one of its affiliates (the "Company") has been granted a patent on its "VEP/PPC" technology. VEP/PPC consists of Vitamin E phosphate combined with polyenylphosphatidylcholine in a biologically active delivery system (with sustained-release capability) which protects the actives through the stomach (by micro-encapsulation) and which enables the actives to cross cellular membranes and rapidly distribute to target tissues.
The Company believes that the granting of the patent on VEP/PPC is another validation of the technology's unique and potent properties. Moreover, this event facilitates the Company's being able to take advantage of its major distribution system relationships.
VEP/PPC will be utilized in a number of the Company's product lines and its "Smart Beverages", taking into account the Company's belief that protection and repair of cells is one of the most effective ways to live longer and more vigorously.
The VEP/PPC technology has been shown through in vitro and in vivo tests to be effective in protecting cells from oxidative stress (including stress which occurs as a result of the natural aging process) and exposure to toxins, while such tests reveal that it is particularly potent in the stimulation of cell membrane repair. Oxidative stress causes cell injury, and cell injury is associated with aging, cancer, emphysema, heart disease, Alzheimer's disease, alcoholic liver disease, and drug-induced tissue injury.
The Company believes that VEP/PPC may have wide application, including for pharmaceutical uses, subject to the requisite clinical trials. The Company holds the exclusive, worldwide rights for all uses of VEP/PPC, including nutraceuticals, biotechnologicals, and pharmaceuticals.
The Company's Smart Beverages address certain major consumer product trends, including the emergence of preventative medicine, the aging American population, and increased consumer awareness of diet and health.
Phlo also announced today that it is currently engaged in the preparation of its Form 10-KSB for the fiscal year ended March 31, 2005, including the three quarterly reports for such periods included in that fiscal year, to be filed with the Securities and Exchange Commission. Phlo believes that it will complete these filings in the very near future. However, Phlo cannot make any assurances with respect to the exact dates upon which such filings will be made due to factors normally associated with such a process which are not under the control of Phlo.
Phlo is a biotechnology company and a manufacturer and marketer of products (primarily liquids) containing patented and patents-pending biotechnologies which are sold on a commercial basis to governmental and institutional purchasers and to high volume chain stores, such as supermarkets and drug and convenience stores. Phlo is focusing its technology generation and acquisition efforts on those technologies related to enhancing cognition and personal performance, reducing the effects of aging, and preventing or ameliorating cancer.
Certain statements made herein that are not historical constitute "forward-looking" statements within the meaning of the Private Litigation Reform Act of 1995 and may contain words such as "anticipate," "believe," "expect," "future," "may," "will," "should," "plan," "projected," "intend," and similar expressions to identify such forward-looking statements. Such statements are based on a number of assumptions and on information and estimates supplied to Phlo Corporation by sources currently available to it. Such assumptions and estimates are subject to uncertainties, contingencies, and other factors, many of which are beyond Phlo Corporation's control. Actual results may differ materially from the statements set forth above.